Universitätsklinikum Jena
Universitätsklinikum Jena
Jena, Germany31 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Recruiting | Phase 3 | 2026-10-07 | NCT06338995 | |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | bronchial disorder, bronchiectasis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06872892 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06424288 | |
| A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | acquired idiopathic inflammatory myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Not yet recruiting | Phase 3 | 2026-09-30 | NCT07789015 | |
| Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-09-30 | NCT06571149 | |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Active, not recruiting | Not applicable | 2026-09-30 | NCT05051033 | |
| A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-24 | NCT05748171 | |
| Low INR to Minimize Bleeding With Mechanical Valves Trial | Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-17 | NCT03636295 | |
| Asciminib Frontline Risk Adapted | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 | 2026-09-04 | NCT07804901 | |
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 4 | 2026-09-01 | NCT07788586 | |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-27 | NCT07789574 | |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG | acute myeloid leukemia, chronic myelomonocytic leukemia, graft versus host disease, immune system disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05153226 | |
| Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | bronchial disorder, bronchiectasis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-08-21 | NCT05846230 | |
| Frontline Asciminib Combination in Chronic Phase CML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-18 | NCT03906292 | |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-06-23 | NCT04522544 | |
| Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma | Esophagogastric Adenocarcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-21 | NCT06731803 | |
| Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients | Hemic and Lymphatic Diseases, anemia, hematologic disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Not stated | 2026-04-14 | NCT05582902 | |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-04-13 | NCT03503799 | |
| Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation | Death, Death, Sudden, Death, Sudden, Cardiac, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiac arrest, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-04-01 | NCT05665608 | |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Not stated | 2026-02-17 | NCT06298565 | |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-12 | NCT06163430 | |
| Early Genetic Identification of Obesity | Abnormalities, Multiple, Bardet-Biedl syndrome, Body Weight, Bone Diseases, Developmental, Ciliopathies, Cognition Disorders, Cognitive Dysfunction, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Hyperphagia, Limb Deformities, Congenital, Musculoskeletal Abnormalities, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Pediatric Obesity, Signs and Symptoms, Signs and Symptoms, Digestive, bone disorder, brain disorder, central nervous system disorder, cognitive disorder, dysostosis, eye disorder, hereditary disease, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, nutritional disorder, obesity disorder, obesity due to pro-opiomelanocortin deficiency, overnutrition, polydactyly, psychiatric disorder, retinal disorder, retinitis pigmentosa, syndactyly, synostosis | Active, not recruiting | Not stated | 2025-09-29 | NCT06239064 | |
| CytOSorb TreatMent Of Critically Ill PatientS Registry | Acute-On-Chronic Liver Failure, Chemically-Induced Disorders, Digestive System Diseases, Disease Attributes, Drug Misuse, Drug Overdose, Hemic and Lymphatic Diseases, Hepatic Insufficiency, Infarction, Infections, Inflammation, Lymphohistiocytosis, Hemophagocytic, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Vasoplegic Syndrome, Prescription Drug Misuse, Respiration Disorders, Rhabdomyolysis, Sepsis, Shock, Shock, Cardiogenic, Systemic Inflammatory Response Syndrome, Vasoplegia, acute liver failure, adult acute respiratory distress syndrome, burn, cardiovascular disorder, cytokine release syndrome, heart disorder, histiocytosis, infectious disease, injury, ischemic disease, liver disorder, liver failure, lung disorder, lymphatic system disorder, muscle tissue disorder, musculoskeletal system disorder, myocardial infarction, myocardial ischemia, non-Langerhans cell histiocytosis, pancreas disorder, pancreatitis, psychiatric disorder, respiratory system disorder, substance-related disorder, toxic shock syndrome, vascular disorder | Recruiting | Not stated | 2025-09-11 | NCT05146336 |